The impact of the metabolic syndrome on cardiovascular risk and disease in rheumatoid arthritis
| Autor: | Ahmed Solomon, Patrick H Dessein, Miguel A. González-Gay, Gavin R. Norton, Angela J. Woodiwiss, Barry I Joffe |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
business.industry Insulin medicine.medical_treatment Systemic inflammation medicine.disease Endocrinology Insulin resistance Rheumatology Internal medicine Rheumatoid arthritis medicine Microalbuminuria Hyperuricemia medicine.symptom Metabolic syndrome business Glucocorticoid medicine.drug |
| Zdroj: | Future Rheumatology. 3:335-349 |
| ISSN: | 1746-0824 1746-0816 |
| Popis: | The metabolic syndrome is a cluster of cardiovascular risk factors that are of metabolic origin and include atherogenic dyslipidemia, hypertension and hyperglycemia. This syndrome is generally considered to develop as a consequence of excess adiposity- mediated insulin resistance. In rheumatoid arthritis (RA), apart from excess adiposity, high-grade inflammation, routine glucocorticoid use and subclinical hypothyroidism are further implicated in insulin resistance. Several more recently uncovered metabolic risk factors including microalbuminuria, hypercoagulability, autonomic dysfunction, hyperuricemia, renin–angiotensin activation and raised aminotransferase concentrations prior to methotrexate use are also more prevalent in RA subjects as compared with non-RA subjects, linked to other metabolic syndrome components and/or related to RA characteristics. Suppression of RA disease activity improves metabolic cardiovascular risk. Systemic inflammation, glucocorticoid therapy, hypothyroidism, insulin resistan... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|